Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed.
PURPOSE: This clinical trial is studying the side effects of giving sunitinib before surgery
and to see how well it works in treating patients with localized or metastatic kidney cancer.